Table 1 Characteristics of the included studies
From: Role of the intestinal microbiome in colorectal cancer surgery outcomes
Authors, year | Study design | No. of patients1 | Tumor stage | Microbiome type, tissue sample | Detection method | Bacteria2 | Short-term surgical outcomes | Long-term oncological outcomes | Mean (SD) or median (range) follow-up | Adjustments on covariates |
|---|---|---|---|---|---|---|---|---|---|---|
Flanagan et al., 2014 | Cohort | 32 | Dukes staging A-D | MAM, tumor | Bacterial DNA, qPCR | Fusobacterium nucleatum | Not reported | • Overall survival | 5 years | Not specified |
Flemer et al., 2018 | Cohort | 47 | AJCC I-IV | MAM, tumor | Bacterial DNA, V3-V4 16S rRNA | CAG | Not reported | • Overall survival | 1371 days (67–1792 days) | Tumor stage, age, gender, treatment with chemotherapy and/or radiotherapy and cancer site |
Kosumi et al., 2018 | Cohort | 1313 | AJCC I-IV | MAM, tumor | Bacterial DNA, qPCR | Bifidobacterium | Not reported | • Cancer-specific mortality • Overall mortality | 14.3 years (10–18.3 years) | Microsatellite instability status, CpG island methylator phenotype, long-interspersed nucleotide element-1 methylation, KRAS, BRAF, and PIK3CA mutations. |
Mima et al., 2016 | Cohort | 1069 | AJCC I-IV | MAM, tumor | Bacterial DNA, qPCR | Fusobacterium nucleatum | Not reported | • Cancer-specific mortality • Overall mortality | 10.7 years (7–15.8 years) | Age, sex, year of diagnosis, family history of colorectal carcinoma in a first-degree relative, tumor location, microsatellite instability (MSI, mismatch repair deficiency), CpG island methylator phenotype (CIMP), KRAS, BRAF, and PIK3CA mutations, and LINE-1 hypomethylation (low-level methylation). |
Van Praagh et al., 2017 | Case-control | 118 | Not specified3 | MAM, anastomosis | Bacterial DNA, V3-V4 16S rRNA | All | Anastomotic leakage | Not reported | Not reported | Not specified |
Wei et al., 2016 | Cohort | 180 | AJCC I-IV | MAM, tumor | Bacterial DNA, V4 16S rRNA | All | Not reported | • Overall survival • Disease-free survival | 47 months (36–59 months) | Not specified |
Yan et al., 2017 | Cohort | 208 | AJCC III-IV | MAM, tumor | Bacterial DNA, qPCR | Fusobacterium nucleatum | Not reported | • Cancer-specific survival • Disease-free survival | Not reported | Not specified |
Yu et al., 2017 | Cohort | 296 | AJCC II-III | MAM, tumor | Bacterial DNA, qPCR | Fusobacterium nucleatum | Not reported | • Recurrence-free survival | Not reported | Not specified |